(Q38543122)

4 September 2017

1 reference

title

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient (English)

1 reference

4 September 2017

1

Ola Landgren

1 reference

4 September 2017

Roger G Owen

2

1 reference

4 September 2017

publication date

3 July 2015

1 reference

Cytometry Part B: Clinical Cytometry

4 September 2017

published in

1 reference

4 September 2017

volume

90

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

14-20

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21273

7 January 2021

Identifiers

DOI

10.1002/CYTO.B.21273

1 reference

4 September 2017

1 reference